Immun Inflamm Dis:舌下免疫治疗后鼻拭子中异染性细胞数量减少

2020-06-16 AlexYang MedSci原创

过敏性鼻炎中,过敏原特异性舌下免疫治疗(SLIT)能够减少鼻症状。而SLIT对柳杉花粉病治疗效果的机制仍旧不清楚。最近,有研究人员调查了SLIT治疗柳杉花粉病后异染细胞、嗜酸性粒细胞和中性粒细胞的变化

过敏性鼻炎中,过敏原特异性舌下免疫治疗(SLIT)能够减少鼻症状。而SLIT对柳杉花粉病治疗效果的机制仍旧不清楚。最近,有研究人员调查了SLIT治疗柳杉花粉病后异染细胞、嗜酸性粒细胞和中性粒细胞的变化情况。

研究人员凡发现,SLIT能够显著的减少季节前(P<0.001)和季节时(P<0.00001)中度到重度症状。与没有进行SLIT治疗的参与者相比,SLIT治疗参与者在季节前和季节时鼻拭子中异染性细胞数量更低(P分别为0.014和0.00001)。SLIT受试者的嗜酸性粒细胞数量则于没有进行治疗的受试者相比在季节前和季节时没有显著差异(P分别为0.29和0.09)。然而,当SLIT受试者分成接受SLIT治疗不小于1.5年或者小于1.5年两组时,嗜酸性粒细胞数量在不小于1.5年组中比没有进行SLIT治疗的受试者显著更低(P=0.011),但在接受SLIT小于1.5年的受试者中不存在(P=0.9)。另外,嗜碱性粒细胞数量在两组之间的鼻拭子中没有显著差异。

最后,研究人员指出,舌下免疫治疗效果的机制之一是异染细胞数量在季节前和季节时的减少。嗜酸性细胞在接受SLIT不小于1.5年的患者中发生减少。

原始出处:

Kuninori Otsuka , Hirokuni Otsuka , Shoji Matsune et al. Decreased Numbers of Metachromatic Cells in Nasal Swabs in Japanese Cedar Pollinosis Following Sublingual Immunotherapy. Immun Inflamm Dis. 28 May 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013400, encodeId=99812013400da, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 03 19:40:25 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057683, encodeId=bbc2205e68378, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 19:40:25 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454864, encodeId=4cdd1454864d7, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu Jun 18 04:40:25 CST 2020, time=2020-06-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013400, encodeId=99812013400da, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 03 19:40:25 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057683, encodeId=bbc2205e68378, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 19:40:25 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454864, encodeId=4cdd1454864d7, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu Jun 18 04:40:25 CST 2020, time=2020-06-18, status=1, ipAttribution=)]
    2021-02-17 lxg951
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013400, encodeId=99812013400da, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Dec 03 19:40:25 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057683, encodeId=bbc2205e68378, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Wed Feb 17 19:40:25 CST 2021, time=2021-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1454864, encodeId=4cdd1454864d7, content=<a href='/topic/show?id=ca5f12e51d4' target=_blank style='color:#2F92EE;'>#NFL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12751, encryptionId=ca5f12e51d4, topicName=NFL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90805606164, createdName=xiaoyeshuang, createdTime=Thu Jun 18 04:40:25 CST 2020, time=2020-06-18, status=1, ipAttribution=)]
    2020-06-18 xiaoyeshuang

相关资讯

Int Forum Allergy Rhinol:常年性鼻炎儿童的特异性舌下免疫治疗分析

过敏性鼻炎(AR)是一个重大的健康问题,并且患者数量在世界范围内增加。过敏性鼻炎影响儿童的学习效率,睡眠质量和其他重要的生活方面。舌下免疫治疗(SLIT)治疗季节过敏性鼻炎是有效的并且是安全的,但是对

Eur Urol:肾细胞肿瘤患者中肠道细菌组成驱使了癌症免疫治疗的原发抗性

免疫检查点阻断(ICB)的发展革命性的改变了肾细胞肿瘤(RCC)的临床结果。尽管如此,治疗响应的持续时间以及预测的改善仍旧没有满足医疗需求。虽然人们已经认识到抗生素(ATBs)在各种恶心肿瘤中能够减少

Am J Otolaryngol:鼻窦疾病是吸入性过敏儿童免疫治疗失败的原因

最近,有研究人员评估了计算机断层扫描评估的鼻窦状况对吸入性过敏原脱敏作用的影响作用。

SCIENCE:人类肿瘤细胞内的细菌竟有细胞特异性!

研究人员对肿瘤微生物组进行了全面的分析,研究了1526个肿瘤及其邻近的正常组织,涉及乳腺癌、肺癌、卵巢癌、胰腺癌、黑色素瘤、骨肿瘤和脑肿瘤等7种肿瘤类型。

Adv Ther:桦树花粉过敏原提取物舌下免疫治疗疗效研究

桦树花粉提取物舌下免疫治疗(SLIT)对过敏性鼻炎(AR)治疗效果很好。但是一个未回答的问题是是否和怎样将临床益处转化为患者益处,比如患者从该治疗中获得什么益处。

Nat Med:晚期肾癌免疫治疗应答不佳机制被揭密

肾透明细胞癌(Clear cell renal cell cancer, ccRCC,最常见的肾癌)是泌尿系统常见的恶性肿瘤之一。目前用于治疗晚期肾癌的免疫检查点抑制剂药物如帕博利珠单抗(Keytru